Showing results (721-730 of 1,873) with videos related to

Sort By:
Pageof 188
Pulmonary Pharmacology & Therapeutics|May 7, 2022
Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteersZhu Luo, Germano Lucci, Luigi Santoro, et al.
Pulmonary Pharmacology & Therapeutics|December 12, 2018
Arbutin attenuates LPS-induced lung injury via Sirt1/ Nrf2/ NF-κBp65 pathwayJinyan Ye, Minqiang Guan, Yao Lu, et al.
Pulmonary Pharmacology & Therapeutics|February 24, 2018
Better airway resistance reduction profile in intubated COPD patients by personalized bronchodilator dosing: A pilot randomized control trialShin-Hwar Wu, Lih-Jen Shyu, Chin-Hsing Li, et al.
Pulmonary Pharmacology & Therapeutics|January 25, 2020
Dual use of bronchodilators versus monotherapy, and its impact on pulmonary rehabilitation in COPD patientsVicente Benavides-Cordoba, Sebastian Aviles, Camila Ascuntar, et al.
Pulmonary Pharmacology & Therapeutics|June 10, 2014
Azithromycin inhibits MUC5AC induction via multidrug-resistant Acinetobacter baumannii in human airway epithelial cellsKoichi Yamada, Yoshitomo Morinaga, Katsunori Yanagihara, et al.
Pulmonary Pharmacology & Therapeutics|November 13, 2012
Statins, systemic inflammation and risk of death in COPD: the Rotterdam studyLies Lahousse, Daan W Loth, Guy F Joos, et al.
Pulmonary Pharmacology & Therapeutics|March 7, 2015
The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to DHuib A M Kerstjens, Gaëtan Deslée, Ronald Dahl, et al.
Pulmonary Pharmacology & Therapeutics|March 27, 2021
Chrysin prevents lipopolysaccharide-induced acute lung injury in mice by suppressing the IRE1α/TXNIP/NLRP3 pathwayMin Chen, Jie Li, Xiaoling Liu, et al.
Pulmonary Pharmacology & Therapeutics|March 28, 2021
Commercial α1-antitrypsin preparations markedly differ in their potential to inhibit the ATP-induced release of monocytic interleukin-1βA Agné, K Richter, W Padberg, et al.
Pulmonary Pharmacology & Therapeutics|August 11, 2020
Fixed-dose combination of three drugs, i.e. LABA/LAMA/ICS for COPD: Results of a real-world study from IndiaSundeep Salvi, Ashish Kumar Deb, Mayank Agarwal, et al.
Pageof 188